• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Astellas to acquire eye drug developer Iveric Bio for $5.9B

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 01, 2023 at 11:32: AM
via Japanese drugmaker Astellas Pharma on Sunday agreed to acquire Iveric Bio for about $5.9 billion, betting that a medicine the biotechnology company has developed for a common type of vision loss can help it build an eye drug business.

article source
 




Top Bottom
Back
Quote